CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study

Prognosis of metastatic triple negative breast cancer (mTNBC) remains poor despite recent advances in therapeutic options. Trastuzumab deruxtecan (T-DXd) has shown promising efficacy in patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer, which is defined by immunohistoch...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yuan, Egelston, Colt, Colunga Flores, Oscar, Chaurasiya, Shyambabu, Lin, David, Chang, Helen, Chong, Leslie Mi Ok, Seiz, Amanda, Shah, Monil, Meisen, W. Hans, Tang, Aileen, Martinez, Norma, Pickett, Wichanee, Murga, Mireya, Yost, Susan E., Stewart, Daphne, Zhang, Jianying, Ede, Nicholas, Modi, Badri, Kessler, Jonathan, Rand, Jamie, Fong, Yuman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640805/
https://www.ncbi.nlm.nih.gov/pubmed/38028143
http://dx.doi.org/10.1177/17588359231210675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640805/
https://www.ncbi.nlm.nih.gov/pubmed/38028143
http://dx.doi.org/10.1177/17588359231210675

Ejemplares similares